Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000708615 | SCV000821751 | pathogenic | Hereditary cancer-predisposing syndrome | 2020-01-01 | criteria provided, single submitter | clinical testing | This variant is a single base pair deletion from exon 21 of the NF1 mRNA, causing a frameshift after codon 819 and this creates a premature translational stop signal 2 amino acid residues later. This is expected to result in an absent or disrupted protein product. Truncating variants in NF1 are known to be pathogenic (PMID: 10712197, 23913538). This variant has been described in the international literature in an individual undergoing panel testing for hereditary syndrome (PMID: 31159747). |
Labcorp Genetics |
RCV001387605 | SCV001588276 | pathogenic | Neurofibromatosis, type 1 | 2024-03-07 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.His819Metfs*2) in the NF1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in NF1 are known to be pathogenic (PMID: 10712197, 23913538). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with personal and/or family history of cancer (PMID: 31159747). ClinVar contains an entry for this variant (Variation ID: 584470). For these reasons, this variant has been classified as Pathogenic. |
Genome- |
RCV001387605 | SCV002561773 | pathogenic | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing |